drugset
drugset / Trial / NCT02303860

Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)

NCT02303860 ↗

Phase 1 Completed 15 enrolled Orion Corporation, Orion Pharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate ORM-12741 concentrations in blood at steady state.

Timeline

Start
2014-10
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ORM-12741 Small molecule — Oral

Indications

No indication recorded.